The clinical potential of prm-PASEF mass spectrometry

Expert Rev Proteomics. 2021 Feb;18(2):75-82. doi: 10.1080/14789450.2021.1908895. Epub 2021 Apr 19.

Abstract

Introduction: The continuous technical improvement in sensitivity and specificity placed mass spectrometry as an alternative method for analyzing clinical samples. In parallel to the rapid development of discovery proteomics, targeted acquisition has been implemented as a complementary option for measuring a small set of proteins with high sensitivity and robustness in a large sample cohort. The combination of trapped ion mobility with a rapid time-of-flight (TOF) mass spectrometer improves the sensitivity even further and triggers the development of prm-PASEF.

Areas covered: This article discusses the development of prm-PASEF and its advantages over the existing targeted and discovery methods for analyzing clinical samples. We are also highlighting the different requirements for the use of prm-PASEF on clinical samples.

Expert opinion: prm-PASEF takes advantage of a dual ion-mobility trap enabling highly multiplexed targeted acquisition. It allows the implementation of a short chromatographic separation setup without sacrificing the number of targeted peptides. Analyzing clinical samples by prm-PASEF holds the promise to significantly improve throughput while maintaining sensitivity to detect the selected target proteins.

Keywords: Ion mobility; biomarker; clinical proteomics; pasef; quantification; targeted proteomics; tims-tof.

MeSH terms

  • Humans
  • Mass Spectrometry
  • Peptides*
  • Proteins
  • Proteomics*
  • Sensitivity and Specificity

Substances

  • Peptides
  • Proteins